M. Ende

发表

Low Nevirapine Plasma Concentrations Predict Virological Failure in an Unselected HIV-1-Infected Population

J. Dieleman, J. Beijnen, A. Huitema, 2003, Clinical pharmacokinetics.

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.

Chapter 3 HIV-1 resistance dynamics in patients with virological failure to dolutegravir maintenance monotherapy .

C. Boucher, R. Schuurman, T. Mesplède, 2018 .

Imiquimod 5% cream for five consecutive days a week in an HIV-infected observational cohort up to 32 weeks in the treatment of high-grade squamous intraepithelial lesions

J. Hollander, M. Ende, E. Snoek, 2015 .

Risk factors and outcome of HIV‐associated idiopathic noncirrhotic portal hypertension

J. Schouten, H. Janssen, J. Verheij, 2012, Alimentary pharmacology & therapeutics.

Effect of gender, race and genotype on interpatient variability in the pharmacokinetics of efavirenz

J. Lindemans, C. Richter, H. Sprenger, 2005 .

Corrigendum to ‘A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption’ [Clin. Immunol. 142 (2012) 252–268]

P. Eilers, A. Osterhaus, J. Aerts, 2014 .

Chapter 2 Dolutegravir as maintenance monotherapy for HIV ( DOMONO ) : a phase 2 , randomised non-inferiority trial

C. Boucher, W. Bierman, H. Bax, 2018 .

High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication.

M. Moroni, D. Cooper, P. Reiss, 1997, The Journal of infectious diseases.

Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe.

A. Wensing, R. Paredes, R. Kaiser, 2015, The Journal of antimicrobial chemotherapy.